Paradigm

Paradigm, founded in 2012, offers personalized therapy for patients with difficult-to-treat cancers through cutting-edge genomic testing. Their Next-Gen Sequencing and biomarker analysis provide detailed information about the genomic and proteomic landscape of a patient’s cancer, allowing for personalized treatment plans based on the specific characterization of the tumor. Paradigm's analysis covers 114 genes with over 500 nucleotides of interest, including DNA mutations, copy number variation, chromosomal inversions, deletions, translocations, and mRNA expression. This information provides physicians and industry partners with precise details about cancer pathways and their associations with specific drugs, enabling more effective decision-making.